Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Meningitis vaccine study gets £200,000 boost

08.02.2008
It can kill in four hours and more than 300 people in the UK die from it every year — and hundreds more are left with permanent disabilities. Now researchers will work on a potential vaccine for meningitis B, thanks to a £200,000 grant from the medical charity Meningitis UK.

Although vaccines exist to protect against some strains of meningitis, there is still no vaccine to protect against all strains, including the most common in the UK — Group B meningococci. This is responsible for almost 90 per cent of all cases and is most common in children under the age of five.

The team, led by Dr Karl Wooldridge, a lecturer in the Centre for Biomolecular Sciences, aim to develop a vaccine against this strain of the bacterium. Group B meningococci mimic molecules in the human body, which makes developing an effective vaccine against this strain very difficult.

Researchers worldwide are searching for alternative antigens — molecules that can stimulate an immune response — on the surface of the bacteria, which could be used as a basis for a vaccine against meningitis B.

The team has identified a series of autotransporter proteins — proteins which are secreted from the surface of Group B meningococci — which could be used to create antibodies that will then kill the bacteria.

The grant will be used to fund a two-year research post, examining each of the proteins produced by the bacteria for the potential to create effective antibodies. The genetic code for each protein will be cloned and tagged, allowing the protein to be produced in large amounts and purified for further study.

“If we identify one or more of these proteins that give a good protective response we would ultimately move to human trials,” said Dr Wooldridge. “This would hopefully demonstrate a positive immune response to the vaccine. By identifying a range of active proteins, rather than just one, we could develop a vaccine that targeted all strains of the Group B meningococci.”

Meningitis UK launched its Search 4 a Vaccine Campaign in 2007 to help raise £7million over the next seven years to fund vital work into developing a vaccine against Group B. This innovative project is just one of the studies the charity is funding.

Meningitis UK’s Chief Executive Steve Dayman said: “We are extremely pleased to be funding Dr Karl Wooldridge and his team in their work to discover more about the proteins secreted by the Meningitis B bacteria. If this research can go forward to help develop a vaccine, thousands of lives could be saved.

“Meningitis can be incredibly hard to detect as many of its symptoms are often similar to more minor ailments such as the common cold or flu, plus there are occasions when people show no, or very few, symptoms. For these reasons, we believe the only way to eradicate meningitis completely is through the development of a preventative vaccine.”

Emma Thorne | alfa
Further information:
http://www.nottingham.ac.uk

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>